If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
reembolso del 75% del coste de Búsquedas e Informes Tecnológicos de Patentes. Más información*
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
139
results.
Updated on
01/09/2024 [07:08:00]
Results 75 to 100 of 139
Absstract of: MX2021008767A
The invention relates to a device (1) comprising a measuring unit (2) with a measuring module (4) for measuring the glucose level, a first computer module (5) for processing data from a first part of the process for measuring the glucose level, a first communications module (6), a first data storage module (7) and a pushbutton (8). The device also comprises a personal monitoring unit (3) with second and third communication modules (17, 20), a second computer module (18) for processing data from a second part of the process for measuring the glucose level, an interface module (19) and a second data storage module (22). Also described is a method for non-invasive blood glucose level estimation.
Absstract of: EP3614394A1
Embodiments of a testing method for optimizing a therapy to a diabetic patient comprise collecting at least one sampling set of biomarker data, computing a probability distribution function, a hazard function, a risk function, and a risk value for the sampling set of biomarker data wherein, wherein the probability distribution function is calculated to approximate the probability distribution of the biomarker data, the hazard function is a function which yields higher hazard values for biomarker readings in the sampling set indicative of higher risk of complications, the risk function is the product of the probability distribution function and the hazard function, and the risk value is calculated by the integral of the risk function, minimizing the risk value by adjusting the diabetic patient's therapy, and exiting the testing method when the risk value for at least one sampling set is minimized to an optimal risk level.
Absstract of: US2024245326A1
An apparatus comprising a pump configured to deliver insulin, an input configured to receive blood glucose data, a user interface, and a controller communicatively coupled to the pump, the input, and the user interface. The controller includes a blood glucose data module to compare the blood glucose data to a target blood glucose level for an insulin pump user. The controller is configured to present a question related to the blood glucose level via the user interface when the blood glucose level is different than the target blood glucose level, receive a response to the question via the user interface, and present a recommended user action based at least in part on the response. Other devices, systems, and methods are disclosed.
Absstract of: US2024245856A1
Rapidly administered emergency drug therapy represents life-saving treatment for a range of acute conditions including hypoglycemia, anaphylaxis, and cardiac arrest. A miniaturized (e.g., <3 cm3), lightweight (e.g., <2 g), minimally invasive fully wireless, emergency rescue device for the storage and active burst-release of indefinitely stable particulate forms of peptide and hormone drugs into subcutaneous sites for direct reconstitution in interstitial biofluids is disclosed. The device demonstrates a fast (e.g., <5 minutes) therapeutic effect. The device may deliver a drug across fibrotic tissue, which commonly accumulates following in vivo implantation, thereby accelerating systemic delivery. Fully wireless delivery of dry particulate glucagon in vivo is demonstrated, providing emergency hypoglycemic rescue in diabetic mice. Additionally, triggered delivery of epinephrine is demonstrated in vivo. Additionally, disclosed herein is a platform for the long-term in vivo closed loop delivery of emergency rescue drugs.
Absstract of: WO2024155345A1
Rapidly administered emergency drug therapy represents life-saving treatment for a range of acute conditions including hypoglycemia, anaphylaxis, and cardiac arrest. A miniaturized (e.g., < 3 cm3), lightweight (e.g., < 2 g), minimally invasive fully wireless, emergency rescue device for the storage and active burst-release of indefinitely stable particulate forms of peptide and hormone drugs into subcutaneous sites for direct reconstitution in interstitial biofluids is disclosed. The device demonstrates a fast (e.g., < 5 minutes) therapeutic effect. The device may deliver a drug across fibrotic tissue, which commonly accumulates following in vivo implantation, thereby accelerating systemic delivery. Fully wireless delivery of dry particulate glucagon in vivo is demonstrated, providing emergency hypoglycemic rescue in diabetic mice. Additionally, triggered delivery of epinephrine is demonstrated in vivo. Additionally, disclosed herein is a platform for the long-term in vivo closed loop delivery of emergency rescue drugs.
Absstract of: US2024245913A1
An illustrative hearing system may include a housing having at least one light source and at least one detector. The at least one light source may be configured to emit a first light having a first excitation frequency and a second light having a second excitation frequency toward tissue at the ear. The at least one detector may be configured to detect intensities of the first light at frequencies offset from the first excitation frequency after the first light has been scattered by the tissue and intensities of the second light at frequencies offset from the second excitation frequency after the second light has been scattered by the tissue. A processing unit may be configured to determine, based on the intensities of the first light and the second light, a glucose value representative of a glucose concentration within the tissue.
Absstract of: WO2024155579A1
The disclosure describes devices and methods for insertion and delivery of insulin or an insulin analog formulation and measurement of subcutaneous glucose concentration. A device for delivery of insulin or an insulin analog formulation and measurement of subcutaneous glucose concentration, may comprise: (a) a tube comprising a proximal end and a distal end, wherein the proximal end is in fluid communication with a source of the insulin or insulin analog formulation, and wherein the distal end is configured to deliver the insulin or insulin analog formulation subcutaneously; (b) a glucose sensor disposed along a central axis of the tube; and (c) a penetrating body disposed along the central axis of the tube, wherein the penetrating body comprises a cross-sectional area no more than a cross-sectional area of the glucose sensor.
Absstract of: US2024245361A1
Disclosed herein are techniques related to glucose estimation without continuous glucose monitoring. In some embodiments, the techniques may involve receiving input data associated with a user. The input data may comprise discrete blood glucose measurement data associated with the user, activity data associated with the user, contextual data associated with the user, or a combination thereof. The techniques may also involve using an estimation model and the input data associated with the user to generate one or more estimated blood glucose values associated with the user.
Absstract of: US2024249811A1
Adaptive on board estimation of exogenous pharmacon responsive to transient (i.e., impermanent) physiological effects is provided. Dynamically estimating an equivalent amount of an exogenous pharmacon on board (XOB), such as insulin and/or carbohydrates, left in the subject, is based on predictions of glucose time-series data. These estimated values, such as insulin on board (IOB), are useful for diabetes management software, including decision support and/or artificial pancreas (AP) algorithms, for example.
Absstract of: US2024249810A1
An insulin delivery rate converter includes a comparator and an insulin delivery supervisor. The comparator is configured to receive insulin data and glucose data and to determine a difference delta between (i) estimations of metabolic data and behavior data derived from the insulin data and blood glucose measurements; and (ii) estimations of metabolic data and behavior data derived from the insulin data without use of the blood glucose measurements. The insulin delivery supervisor is configured to modulate an insulin delivery rate based at least in part on the difference delta determined by the comparator.
Absstract of: US2024245850A1
A system and method can provide for a remote electronic device to be used to remotely initiate delivery of a medicament bolus with a medical device, such as an insulin pump, with the medical device providing audible or tactile confirmation of the programmed bolus. The bolus amount can be calculated by or programmed or otherwise entered into the smartphone, etc., and then transmitted to the medical device. When the pump receives the transmitted bolus amount, it issues one or more indications such as audible sounds and/or vibrations in any number of desired combinations. For instance, each individual sound or vibration may correspond to an increment of the medicament. The user can therefore determine the size of the medicament bolus by the number of sounds or vibrations and can confirm or cancel delivery of the bolus.
Absstract of: US2024245849A1
An insulin monitoring system includes one or more processors, one or more computer-readable storage devices, and program instructions stored on at least one of the one or more storage devices for execution by at least one of the one or more processors. The program instructions include: first program instructions to track, in real time, the amount of insulin active in a patient; second program instructions to calculate the amount of insulin need of the patient by tracking the patient's metabolic states; third program instructions to compare the insulin active in the patient with the insulin need of the patient; and fourth program instructions to determine an insulin fault level based on the comparison.
Absstract of: US2024249812A1
Method and system for providing diabetes management and insulin therapy based on substantially real time glucose monitoring system is provided.
Absstract of: WO2023044347A1
A device for continuously monitoring glucose levels in a patient is disclosed. The device includes a glucose electronics assembly and a glucose lead assembly in electrical communication with the glucose electronics assembly. The glucose electronics assembly is configured to be positioned in the subcutaneous tissue and the glucose lead assembly is configured to be positioned in a vessel of the patient. The glucose lead assembly has a central shaft, a first electrode in physical communication with the central shaft, a second electrode in physical communication with the central shaft, a third electrode in physical communication with the central shaft and a positioning element configured to have an undeployed state and a deployed state. In the undeployed state, the positioning element is substantially linear, and in the deployed state, the positioning element extends away from the central shaft.
Absstract of: CN117979897A
A device for determining a glucose level of a patient includes a set of electrodes including a first working electrode, a second working electrode, a counter electrode, and a reference electrode. The reference electrode is electrically coupled to the counter electrode. The apparatus also includes a memory and one or more processors implemented in a circuit and in communication with the memory. The one or more processors are configured to determine a sensor signal based on a current flowing between the first working electrode and the counter electrode, and to determine an open circuit potential (OCP) signal based on a voltage across the second working electrode and the reference electrode. The one or more processors are further configured to determine the glucose level of the patient based on the sensor signal and the OCP signal, and output an indication of the glucose level.
Absstract of: EP4404210A2
Systems, devices, and methods are provided for the control of interfacing between applications that facilitate the monitoring of diabetes running on a mobile device, including the authentication of a third party user interface application by a sensor interface application. Control of the display of current analyte levels and critical events is also provided.
Absstract of: EP4404212A2
Continuous glucose monitoring (CGM) data and insulin delivery data are used to generate more reliable projected alarms related to a projected glucose levels. A memory stores endogenous data related to measurements of glucose level in a patient, and also stores exogenous data, such as insulin on board, both of which are used by a processor to create projected alarms. Profiles of CGM data are created for use in tuning patient-specific insulin data, such at basal rate, carb ratio, and insulin sensitivity. A processor searches for patterns in the data profiles and if found, recommended changes to patient-specific insulin data are provided to permit more accurate control over a patient's glucose levels.
Absstract of: US2024237913A1
The present invention relates to a portable breath analysis device system and a method thereof that helps healthy nutrition and weight loss by allowing for detecting the intolerant foods by means of analyzing the respiratory gases received from the person's breath. The present invention particularly relates to a portable breath analysis device system and a method thereof that simultaneously and instantaneously measures acetone, ammonia, nitric oxide, ethanol, carbon monoxide, and hydrogen gases in the breath of a person, that allows for monitoring and regulating a person's carbohydrate (sugar), fat, and protein consumption with a computer-based method by transferring the data obtained from these measured gases to a mobile device.
Absstract of: US2024242834A1
Described herein are methods and systems for preventing a glycemic event. One or more improved deep-learning models for predicting glycemic events may receive current blood glucose data and other physiological data from associated with a patient. The one or more models may determine one or more future blood glucose values and whether or not the one or more future blood glucose values satisfy one ore more thresholds associated with one or more glycemic events (e.g., hypoglycemia and/or hyperglycemia). If the one or more future blood glucose values satisfy the one or more thresholds, one or more actions may be taken (e.g., administration of insulin).
Absstract of: US2024237925A1
A method of data analysis is provided. The method is used for finding a long-term trend of blood glucose concentration. The method builds a model for estimating long-term glycemic variability and long-term blood glucose trajectory. Based on single-erythrocyte-level glycated hemoglobin distribution, the glycemic variability is analyzed. A first analysis method is to give a number. The number shows the level of the historical glycemic variabilities. A second analysis method is to restore the blood glucose trajectory over the past 20 weeks. Based on the single-erythrocyte-level glycated hemoglobin distribution, the present invention easily assesses blood-glucose-related clinical information for about 150 days. Hence, an important complement is obtained for diabetes-related or glucose-monitoring-related clinical applications.
Absstract of: WO2024151534A1
Systems and methods for displaying metrics related to a user are described. Data indicative of glucose levels of the user is received. A first alert point for a potential glucose episode in a data set of time correlated glucose data, e.g., a glucose vs. time curve, is identified if the last received glucose data point satisfies at least one alert condition. A first potential local minimum in a first time period is identified. The first potential local minimum is confirmed as a first start point of a first glucose episode if the first potential local minimum satisfies at least one local minimum condition. An integrated area under the curve over time of a first portion of the graph beginning at the first start point of the first glucose episode to the first alert point is calculated. A first count value is assigned to the first portion.
Absstract of: US2024239861A1
This invention relates to isolated polypeptides that are glucagon-receptor selective analogs and peptide derivatives thereof. These analogs are selective for human glucagon receptor with improved solubility, thermal stability, and physicochemical properties as compared to native endogenous glucagon. This invention also relates to methods of using such polypeptides in a variety of therapeutic and diagnostic indications, as well as methods of producing such polypeptides. These analogs are useful, alone or in combination with other therapeutic peptides, in methods of treating obesity, diabetes, metabolic disorders, and other disorders or disease.
Absstract of: WO2024151537A1
Systems and methods for monitoring glucose variability are described. Data indicative of glucose levels of the subject is received. A first glucose metric is determined in a first time period. A second glucose metric is determined in a second time period. A difference between the second and first glucose metrics are determined. The difference is compared to a threshold. A first indicator is displayed if the difference does not exceed the threshold and a second indicator is displayed if the difference exceeds the threshold. In some embodiments, the indicator is one of a balanced state or a steady state and the second indicator is one of an unbalanced state, an unsteady state, a not steady state, or a spiky state.
Absstract of: CN115779184A
The invention discloses an interlocking type medicine infusion device which comprises a medicine storage cylinder used for containing medicine, and a piston and a screw are arranged in the medicine storage cylinder; the driving wheel is connected with the screw rod and drives the screw rod to push the piston to advance by rotating the screw rod; the driving unit moves in the driving direction to drive the driving wheel to rotate; the driver is electrically connected with the driving unit, and the electrified linear driver is used for providing power for the driving unit in the driving direction; the program module is electrically connected with the driver and provides a first driving instruction for controlling the driver to perform periodic power output; and the position detection module is used for determining the periodic medicine infusion amount, and when the medicine infusion amount reaches a set threshold value, the position detection module and/or the program module provide a second driving instruction for the driver. The program module and the position detection module physically form a synchronous interlocking mechanism, so that the risk of hypoglycemia and even coma caused by excessive infusion under the condition that an electronic component or a preset program fails is prevented.
Nº publicación: EP4401084A2 17/07/2024
Applicant:
INSULET CORP [US]
Insulet Corporation
Absstract of: EP4401084A2
Disclosed are techniques, devices and systems that implement and utilize a voice control application and sound chip circuitry to control operation of a wearable drug delivery device. In addition, a wearable drug delivery device equipped with the sound chip circuitry may be operable to play audio clips that may include content for assisting a user with an initial set up of the wearable drug delivery device, providing messages of encouragement, lullabies for pediatric users, and the like. In addition, the voice control application enables users to control delivery of liquid drugs via a wearable drug delivery device hands-free using voice commands and voice confirmations of actions to be taken by an automated insulin delivery application.
BOPI
Electronic site
